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Abstract
Background: Protein expression in Escherichia coli may result in the recombinant protein being expressed as
insoluble inclusion bodies. In addition, proteins purified from E. coli contain endotoxins which need to be removed
for in vivo applications. The structural protein, E2, from Bovine Viral Diarrhoea Virus (BVDV) is a major immunogenic
determinant, and is an ideal candidate as a subunit vaccine. The E2 protein contains 17 cysteine residues creating
difficulties in E. coli expression. In this report we outline a procedure for successfully producing soluble and
endotoxin-free BVDV E2 protein from inclusion bodies (IB).
Results: The expression of a truncated form of BVDV-E2 protein (E2-T1) in E. coli resulted in predominantly
aggregated insoluble IB. Solubilisation of E2-T1 with high purity and stability from IB aggregates was achieved
using a strong reducing buffer containing 100 mM Dithiothreitol. Refolding by dialysis into 50 mM Tris (pH 7.0)
containing 0.2% Igepal CA630 resulted in a soluble but aggregated protein solution. The novel application of a
two-phase extraction of inclusion body preparations with Triton X-114 reduced endotoxin in solubilised E2-T1 to
levels suitable for in vivo use without affecting protein yields. Dynamic light scattering analyses showed 37.5% of
the protein was monomeric, the remaining comprised of soluble aggregates. Mice immunised with E2-T1
developed a high titre antibody response by ELISA. Western hybridisation analysis showed E2-T1 was recognised
by sera from immunised mice and also by several BVDV-E2 polyclonal and monoclonal antibodies.
Conclusion: We have developed a procedure using E. coli to produce soluble E2-T1 protein from IB, and due to
their insoluble nature we utilised a novel approach using Triton X-114 to efficiently remove endotoxin. The
resultant protein is immunogenic and detectable by BVDV-E2 specific antibodies indicating its usefulness for
diagnostic applications and as a subunit vaccine. The optimised E. coli expression system for E2-T1 combined with
methodologies for solubilisation, refolding and integrated endotoxin removal presented in this study should prove
useful for other vaccine applications.
Background
Bovine viral diarrhoea virus (BVDV) infection of cattle is
linked to economically important diseases with losses in
the USA being estimated to US$10-40 million per mil-
lion calves [1] and US$6 million per million calves in
the UK [2]. BVDV is a member of the Pestivirus genus
within the Flavivirus family. The BVDV genome is a
positive sense RNA molecule with one open reading
frame (ORF) encoding for a polyprotein which is cleaved
into the structural and non-structural proteins [3]. Of
the structural proteins, the surface glycoprotein, E2 is a
major immunogenic determinant and is involved in
virus neutralisation [4]. E2 is therefore an ideal candi-
date for use in subunit vaccines [5,6].
E2 contains 17 cysteine residues which form both
intramolecular disulphide bonds and intermolecular dis-
ulphide bonds resulting in dimers of E2-E2 and E2-E1
[7]. For a protein with high disulphide bond formation,
recombinant protein expression is best attempted in
mammalian and insect cell systems [8]. Expression of E2
has been documented in mammalian [5,9] as well as
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[12]. Mammalian and insect cell line expression of pro-
teins have the advantage of producing proteins with cor-
rect conformation and post-translational modifications
such as glycosylation, but generally yields are lower than
Escherichia coli systems. However, the low costs
required for veterinary vaccine applications preclude the
use of more expensive protein expression systems such
as mammalian and insect cell systems [13]. The use of
E. coli based expression systems is hindered by the fact
that although the recombinant proteins are generally
expressed at high yields the resulting proteins are often
insoluble and lack post-translational modifications [8].
Expression of glycosylated proteins in E. coli has been
previously reported, Chia et al. [14] demonstrated the
successful generation of neutralising antibodies to the
envelope protein (E) of Japanese Encephalitis Virus
(JEV), also a member of the Flavivirus family. Das et al.
[15] demonstrated monoclonal antibodies generated
against E. coli expressed Ebola virus antigen recognised
the glycosylated antigen expressed in mammalian cells.
Expression of recombinant proteins in E. coli often
leads to insoluble aggregates known as IB [16]. Though,
usually seen as an undesirable effect, recent research has
shed light on advantages of IB formation [17]. Further-
more as IB aggregates are observed due to intermolecu-
l a ri n t e r a c t i o n sa m o n gas i n g l et y p eo fp r o t e i n ,t h e
formation of IB can aid in the purification and isolation
of the expressed protein [18]. IB aggregates are common
in proteins containing disulphide bonds (such as E2), as
the reducing environment of the bacterial cytosol inhi-
bits the formation of disulphide bonds [8,19]. IB solubi-
lisation is generally achieved by the use of chaotropic
agents, such as urea and guanidine salts, and/or deter-
gents and reducing agents. Refolding of the protein can
be achieved by dilution or dialysis into suitable buffers
that may contain detergents, oxidising or reducing
agents and other additives to maintain solubility and to
facilitate correct folding of the protein [19,20].
A potential drawback from the production of recombi-
nant proteins in E. coli is contamination with endotox-
ins. Endotoxins are a major component of gram
negative bacterial cell walls and are liberated during
extraction of proteins [21]. Endotoxins are heat stable
lipopolysaccharides with monomer molecular weights
ranging from 10 to 20 kDa and form highly stable
aggregates [21]. Mammalian exposure to endotoxins can
induce several undesirable physiological effects such as
fever, leukocytosis, hypoferremia, platelet aggregation,
thrombocytopenia and coagulapathies [22]. Common
methods employed for the removal of endotoxins from
protein purifications include ultrafiltration, adsorption
techniques, affinity chromatography and Triton X-114
two-phase extraction [21,23]. Two-phase extraction with
Triton X-114 showed 98-99% reduction of endotoxin
levels for the soluble proteins cardiac troponin I, myo-
globin and creatin kinase with a protein recovery of >
90% [24]. Aida and Pabst [25] demonstrated a 1000
fold reduction of endotoxin for the soluble proteins
catalase, cytochrome c, and bovine serum albumin
using this method with a protein loss of 2% for cyto-
chrome c.
In this study, we report the expression and purifica-
tion of a truncated form of the BVDV E2 protein (E2-
T1) from IB aggregates and optimised solubilisation
conditions for this protein. We also describe a novel
process for the removal of endotoxins from IB aggre-
gates using Triton X-114 phase-partitioning to maxi-
mise E2-T1 yields. The suitability of this E2-T1
protein for small animal vaccination in mice is also
demonstrated.
Results
Cloning and Expression
A truncated version of the E2 ORF frame was produced
using PCR to remove the 3’ region of the ORF which
encodes for the membrane binding domain. The resul-
tant 1040 bp PCR product was ligated into pET-SUMO
expression vector.
Sequence analysis of pET-SUMO-E2-T1 demonstrated
the vector encoded start codon, SUMO tag and 6-His
region were in frame with E2-T1. The fusion protein
encoded by pET-SUMO-E2-T1 has 463 residues; the
amino acid composition is shown in Table 1. ProtParam
was used to calculate the molecular weight and theoreti-
cal isoelectric point (pI) which were determined as 52.5
kDa and 6.22 respectively.
Pilot expression studies indicated auto-induction of
E2-T1 as insoluble protein at 0 hours. (Figure 1A, B).
The optimal expression of E2-T1 was at 37°C, 2 hours
post induction with 1 mM IPTG (Figure 1B). The
majority of the E2-T1 protein was contained within the
insoluble pellet fraction as inclusion bodies (Figure 1A).
Table 1 Amino Acid composition of E2-T1
Amino acid Number of
residues
Amino acid Number of
Residues
Ala (A) 24 Leu (L) 32
Arg (R) 27 Lys (K) 31
Asn (N) 13 Met (M) 14
Asp (D) 33 Phe (F) 22
Cys (C) 17 Pro (P) 24
Gln (Q) 19 Ser (S) 23
Glu (E) 31 Thr (T) 30
Gly (G) 37 Trp (W) 6
His (H) 15 Tyr (Y) 16
Ile (I) 22 Val (V) 27
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Purification of E2-T1 from the soluble protein fraction
was attempted using TALON resin. A step gradient of
imidazole (50, 80, 100 and 150 mM) was used to deter-
mine the optimum elution profile. At 150 mM imida-
zole, E2-T1 was the major species eluted from the
column. This eluted protein was of high purity but of
low yield (10 ng/μL).
The majority of the E2-T1 protein was present in the
insoluble fraction (Figure 1A, B). Using BugBuster™ it
was possible to prepare soluble, high purity E2-T1 from
the IB. E2-T1 protein was successfully dissolved in a
DTT-SDS buffer (50 mM Tris (pH 6.8), 100 mM DTT,
1% SDS, 10% Glycerol). Titration of DTT concentrations
using 5, 10 and 20 mM revealed a degree of solubility at
all DTT concentrations; however, only at 100 mM DTT
was the entire fraction of E2-T1 protein consistently
solubilised (data not shown).
Refolding of E2-T1 protein was achieved by dialysis in
50 mM Tris (pH 7.0), 0.2% Igepal at room temperature.
The resultant protein had high purity (Figure 1A, lane
6) with an average yield of 1-2 mg protein/litre of bac-
terial culture and was highly stable. E2-T1 stored at -20°
C showed no degradation after more than 12 months
and was resistant to degradation at room temperature
for 7 days (data not shown).
Dynamic light scattering (DLS) analysis of purified E2-
T1 demonstrated it to be a polydispersed protein with a
polydispersity index (PdI) of 0.528 ± 0.041 indicating
protein aggregation. The size distribution graph (Figure
2A) shows multiple species, a consistent major peak
(37.5% ± 3.3% intensity) with a hydrodynamic diameter
of 6.04 nm ± 1.65 nm is most likely a monomer species
of E2-T1. This peak corresponds to a hypothetical glob-
ular protein of 44.7 ± 12.2 kDa as calculated by the
Zetasizer software. The remaining peaks between 37 nm
and 458 nm are representative of soluble protein aggre-
gates. Peaks over 4,000 nm are most likely dust particles.
A western blot of E2-T1 run under non-reducing condi-
tions showed bands of 52 kDa and 100 kDa (Figure 2B).
The 52 kDa band is consistent with the monomeric
form as seen in the reducing gel (Figure 1B) and the
100 kDa suggests the formation of dimers of E2-T1.
Initial attempts to refold E2-T1 in 50 mM phosphate
buffer (pH 6.0) and PBS (pH 7.2) were unsuccessful, as
the protein formed insoluble aggregates, the addition of
Igepal CA630 to 0.2% failed to improve protein solubi-
lity in these buffers. However, E2-T1 protein remained
soluble in 50 mM Tris (pH 8.0), 0.2% Igepal CA630 and
50 mM Tris (pH 7.0), although in the absence of Igepal
CA630, E2-T1 showed a much higher level of polydis-
persity (PdI: 0.931 ± 0.075).
Endotoxin Removal
Endotoxin assays measured by Limulus Amebocyte
Lysate (LAL) assay revealed levels ranging from 5.29 to
199.31 EU/mL (Table 2) for untreated batches of E2-T1.
Treatment by phase separation using Triton X-114 on
the insoluble IB pellets resulted in 3 phases: an aqueous
phase, a detergent phase and the IB pellet fraction. Ana-
lysis of all three phases by SDS-PAGE showed that the
protein was retained in the IB pellet with no loss of pro-
tein in the aqueous or oil phases (Figure 3). The result-
ing Triton X-114 treated E2-T1 samples had greatly
reduced endotoxin levels below 3 EU/mL (Table 2). Due
to the validation methods used for the LAL test, an
absolute reading below this minimal threshold value
could not be determined.
Figure 1 Protein analysis of pET-SUMO-E2-T1 expression in E.
coli BL21 (DE3). (A) Protein from soluble and insoluble fractions
separated by electrophoresis on 10% Bis-Tris gel and stained with
Coomassie blue. Lane 1, SeeBlue
® Plus2 MW standard; lane 2,
soluble protein fraction at 0 hours; lane 3, insoluble protein fraction
at 0 hours; lane 4, soluble protein fraction 2 hours post IPTG
induction; lane 5, insoluble protein fraction 2 hours IPTG post
induction; lane 6, E2-T1 purified from IB (0.4 μL); lane 7, E2-T1
purified from IB (2 μL). (B) Western blot image of E2-T1 protein
expressed in E. coli BL21 (DE3). Equivalent amounts of protein from
the soluble and insoluble fractions were transferred to Hybond C
and incubated with an anti-his antibody and detected by ECL. Lane
1, soluble protein fraction 0 hours; lane 2, insoluble protein fraction
0 hours; lane 3, soluble protein fraction 2 hours post IPTG induction;
lane 4, insoluble protein fraction 2 hours post IPTG induction.
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Western hybridisation analyses showed solubilised E2-T1
protein was recognised by antibodies raised against
BVDV in sheep and goats as well as 3 BVDV-E2 mono-
clonal antibodies, mAb-157, mAb-348 and mAb-9-D4
(Figure 4), the monoclonal mAb-89 failed to detect E2-
T1 (Figure 4). To determine whether the bacterially
expressed E2-T1 would be useful as a subunit vaccine
candidate, mice were immunised with 50 μg purified E2-
T1 in combination with 10 μg of QuilA subcutaneously
in the tail base at 2 week intervals. The immune response
was titrated by ELISA and Western blot analysis. The E2-
specific antibody response by ELISA showed that follow-
ing two injections the response is variable (yellow bars
Figure 5A). However, after a third injection of E2-T1 pro-
tein an excellent humoral immune response in all 4 mice
was detected (black bars Figure 5A).
The terminal bleed serum from one animal with the
highest ELISA response was used in Western hybridisa-
tion analyses to E2-T1. Preimmune sera from this ani-
mal showed no reactivity at 1:200 and 1:4000 dilution
(Data not shown). Specific detection of E2 protein
Figure 2 (A) Dynamic Light Scattering analysis of E2-T1. E2-T1 protein was dialysed into 50 mM Tris (pH 7.0) containing 0.2% Igepal CA630.
The graph shows size distribution by intensity for physical size determination. Six measurements of 30 readings each were performed. (B)
Western blot of purified E2-T1. E2-T1 protein was run under non-reducing conditions and probed with mouse sera raised against E2-T1.
Table 2 Purified protein concentrations and endotoxin
levels
Sample ID Protein Concentration
ng/μL
Endotoxin Level
EU/mL
1 200.80 110.32
2 279.15 199.31
4 265.32 29.91
5 92.50 5.29
6a* 76.92 < 3
6b* 111.34 < 3
7a* 74.16 < 3
7b* 138.88 < 3
* Samples treated with Triton X-114.
Figure 3 Protein fractions following endotoxin removal from
E2-T1 IB by Triton X-114 extraction were separated by
electrophoresis on 10% Bis-Tris gel and stained with
Coomassie blue. Lane 1, SeeBlue
® Plus2 MW standards; lane 2, IB
pellets resuspended in PBS before Triton X-114 treatment; lane 3,
aqueous layer post Triton X-114 treatment; lane 4, recovered IB
pellet post Triton X-114 treatment; lane 5, Triton TX-114 layer.
Cavallaro et al. Microbial Cell Factories 2011, 10:57
http://www.microbialcellfactories.com/content/10/1/57
Page 4 of 9was detected at high titre (1:64000) with mouse serum
(Figure 5B). Non-specific bands were also observed,
although E2-T1 was the dominant reactive species. The
non-specific bands were not detectable by the preim-
mune sera.
Discussion
The advantages of IB in terms of biological activity and
facilitating protein purification have been highlighted in
recent publications (15, 16). This study describes a pro-
cedure for the expression and solubilisation of a highly
purified viral antigen derivative, E2-T1 from IB. The
methodology includes the efficient removal of endotox-
ins to allow for potential in vivo applications.
In vivo refolding studies of purified E2 have shown
that intramolecular disulphide bonds form rapidly
within 2.5 minutes and intermolecular disulfide bonds
result in formation of E2 dimers [7]. Since disulphide
bonds are inefficiently formed in the reducing environ-
ment of the E. coli cytosol [8] and native E2 rapidly
forms intramolecular disulphide bonds, misfolding of
E2-T1 is likely to form an insoluble protein. Also, for-
mation of intermolecular disulphide bonds between E2-
T1 in the E. coli cytosol would lead to the formation of
aggregates resulting in IB. In our study consistent and
reproducible solubilisation of E2-T1 was only achievable
using a highly reducing buffer containing 100 mM DTT.
At lower DTT concentrations (20 to 5 mM), the percent
solubility of E2-T1 decreased, indicating strong disul-
phide bond formation. The inclusion of DTT as a redu-
cing agent in the re-suspension buffer would disrupt
incorrectly formed disulphide bonds, and then during
dialysis into DTT-free buffer, the disulphide bonds
could reform in a conformation that is more suitable for
soluble protein.
Although refolding of E2-T1 was successful in Tris
based buffers, the resultant protein formed soluble aggre-
gates as indicated by a PdI of 0.931. The soluble aggrega-
tion could be due in part to the same intermolecular
disulphide bond formation reported for native E2. The
addition of the detergent Igepal CA630 (0.2%) to Tris
based buffers reduced aggregation (PdI 0.528), indicating
some aggregation may be due to weaker intermolecular
interactions such as ionic and/or hydrogen bonds. Under
non-reducing electrophoresis conditions (Figure 2B), E2-
T1 shows 2 dominant bands corresponding to mono-
meric and dimeric forms. This corresponds to the
dimeric bonds between dimers arising from disulphide
bond formation and other soluble aggregation is due to
weaker intermolecular interactions. Addition of Igepal
CA360 to PBS (pH 7.2) could not reverse the formation
of aggregates indicating that the presence of Tris may be
critical for maintaining E2-T1 solubility. The fact that a
highly reducing buffer (100 mM DTT) was required to
solubilise E2-T1 IB and the addition of Igepal CA360
could not completely overcome aggregation, lends evi-
dence to strong disulphide bond formation.
Endotoxin levels lower then 3 EU/mL of E. coli
derived proteins have been reported to be safe, causing
Figure 4 Western blot analysis of E2-T1 protein with BVDV-
specific antibodies. Equivalent amounts of protein were
transferred to Hybond C membrane and visualized by ECL. Lane 1,
Precision Plus Protein Kaleidoscope MW standards; lane 2, Anti-His
antibody; lane 3, sheep 804 pre immune sera; lane 4, sheep 804
post immune sera; lane 5, VMRD monoclonal D89; lane 6, VMRD
monoclonal 157; lane 7, VMRD monoclonal 348; lane 8, Linfa Wang
D4/G4 monoclonal; lane 9, VMRD Goat anti BVDV; lane 10, Anti-His
antibody.
Figure 5 Serum analysis from E2-T1 inoculated mice.( A )E L I S A
analysis of mice receiving three injections of E2-T1. Mice (n = 4)
were injected with 50 μg E2-T1 and 10 μg QuilA at 2 week intervals.
ELISA assays were performed using pre-immune sera and sera
obtained two weeks following each injection, termed 1
st,2
nd and
terminal samples. (B) Western blot analysis of E2-T1 with terminal
sera. Mice sera was used at the following dilutions: lane 1, 1:4000;
lane 2, 1:8000; lane 3, 1:16000; lane 4, 1:32000; lane 5, 1:64000; lane
6, VMRD monoclonal 348; lane 7, VMRD monoclonal D89; lane 8,
VMRD monoclonal 157.
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in our case the E2-T1 protein purified from E. coli
resulted in high endotoxin levels between 5.29 - 199.31
EU/mL. This was considered unsuitable for testing E2-
T 1a sac o m p o n e n to fav e t e r i n a r yv a c c i n ed u et ot h e
risk of adverse immunological reactions. Commercially
available techniques for endotoxin removal typically
employ affinity columns and require buffer changes for
washing and elution of the protein. Attempts to use ion
exchange chromatography were discontinued due to
consistently low recovery of E2-T1.
We introduced a significantly innovative step for
endotoxin removal from the E. coli IB by adding Triton
X-114 in the E2-T1 expression and purification protocol
prior to solubilisation and recovery of the target protein.
Phase separation with Triton X-114 resulted in up to
600 fold reduction in the endotoxin levels of the E2-T1
preparations (Table 2). Importantly, using this method
resulted in no detectable E2-T1 loss (Figure 3), as the
protein remained insoluble within the IB. This approach
could be generally applicable for the efficient removal of
endotoxins from other proteins contained within IB pre-
parations, by maintaining the IB in a buffer incompati-
ble with the solubilisation of the target protein, while
still facilitating endotoxin removal with Triton X-114.
We have shown that E2-T1 protein produced in E. coli
was recognised by antibodies raised in goat and sheep
against whole BVDV and also by various BVDV-specific
monoclonal antibodies (Figure 4) indicating the useful-
ness of E2-T1 for diagnostic applications such as moni-
toring the serological status of animals which are the
natural host of BVDV. Furthermore an ELISA done using
E2-T1 against 5 BVDV infected cattle sera samples with
known serum neutralisation titres showed that E2-T1
is recognised by cattle sera at a comparable level to the
commercial positive control sera (data not shown).
One monoclonal antibody, mAb-D89, did not recog-
nise E2-T1, which could be due to its binding to either
a conformational E2 epitope or an epitope that is depen-
dent on post-translational modification of E2 such as
glycosylation. As the binding capacity of mAb-D89 was
only assessed under denaturing and reducing conditions
this could have caused the loss of the mAb-D89 epitope
from the renatured E2-T1. It remains to be determined
how the potential loss of spatial and other non-linear
epitopes of native E2 would affect the efficaciousness of
any vaccine formulations containing E2-T1.
Immunisation of mice with bacterially derived E2-T1
protein resulted in an excellent immune response, con-
firmed both by ELISA assay and Western blot hybridisa-
tion. Western blot analysis with mouse sera collected
after three immunisations with E2-T1 resulted in very
strong detection of E2 protein with significant bands
readily detectable at a 1:64000 dilution. The predominant
lower molecular weight band (approximately 45 kDa)
observed by Western hybridisation (Figure 5B) may be
due to the polyclonal nature of the antibodies and are
not present when probed with pre-immune sera.
The results of this study demonstrate that the bacte-
rially derived E2-T1 protein solubilised from IB can
induce an excellent humoral response in small animals
and could potentially be used as a subunit vaccine. The
next step will be to determine if E2-T1 can elicite simi-
lar responses in large animals such as sheep or cattle
when evaluated as a potential vaccine antigen.
Conclusion
The development of cost effective veterinary vaccines
and diagnostics requires the use of efficient methods
that enable the production of large quantities of immu-
nogenic and non-toxic proteins. Using an E. coli system
and exploiting the formation of IB, we were able to pro-
duce a highly pure, stable and endotoxin-free E2-T1
protein. It was highly immunogenic in mice and was
recognised by BVDV-E2 specific antibodies raised to
native E2 in BVDV. We have developed a procedure for
solubilising and refolding E2-T1 as well as the removal
of endotoxin by Triton X-114 two-phase extraction
which offers an elegant solution for the production of
other proteins intended for diagnostic uses and in vivo
uses such as subunit vaccines or therapeutics.
Methods
Cloning of E2-T1 into pET-SUMO bacterial expression
vector
The E2 gene was amplified from a plasmid containing
BVDV isolate MD74 which has been identified as a type-
1 isolate [28]. Twenty μL of Qiagen (Venlo, The Nether-
lands) PCR master mix was used with primers at a final
concentration of 0.5 μM. The forward primer nanoE2-F
sequence was 5’-ATGGTGGATCCGTGCAAGCCT-3’
and the reverse primer nanoE2-Rtrunc1 sequence was 5’-
CTAAGACTCGGCGAAGTAGTC CCGG-3’.P C R
cycling conditions comprised an initial incubation at 95°C
for 5 minutes, followed by 35 cycles at 94°C for 30 sec-
onds, 60°C for 30 seconds and 72°C for 90 seconds. The
r e s u l t a n t1 0 4 0b pp r o d u c tw a sl i g a t e di n t ot h ep E T -
SUMO vector (Invitrogen, Carlsbad, USA). The ligation
products were subsequently transformed into electrocom-
petent E. coli strain DH10B (Invitrogen). Positive clones
were confirmed by sequencing (AGRF, Brisbane, Austra-
lia) and transformed into E. coli strain BL21 (DE3, Invi-
trogen) cells for protein expression.
Large-scale expression and purification of E2-trunc1
protein
An overnight culture of E. coli BL21 (DE3) containing
pET-SUMO-E2-T1 was used to inoculate four 250 mL
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taining 50 mg/L Kanamycin-sulphate (Amresco). These
c u l t u r e sw e r eg r o w na t3 7 ° Ct oa nO D 600 of 0.4 to 0.6,
then induced with 1 mM IPTG and grown for a further
2 hours. The bacterial pellet was collected by centrifuga-
tion at 3,800 g, at 4°C for 15 minutes in 4 × 250 mL
centrifuge tubes. Total protein was extracted by resus-
pending each bacterial pellet in 50 mL E. coli lysis buffer
(50 mM KPO4 phosphate (pH 7.8), 400 mM NaCl, 100
mM KCl, 10% glycerol, 0.5% Triton X-100, 10 mM Imi-
dazole), with the addition of 12.5 mg Lysozyme and 750
units of Benzonase nuclease (Novagen-Merck, Darm-
stadt, Germany). The bacterial suspensions were incu-
bated in lysis buffer for 20 minutes with gentle shaking.
The samples were frozen in liquid nitrogen, and thawed
at 42°C three times. The resultant solution was centri-
fuged at 37,000 g at 4°C for 15 minutes. The insoluble
protein fraction (containing IB aggregates) and the
supernatant (containing the soluble protein fraction)
were stored at -20°C until required.
Purification of soluble E2-T1
E2-T1 protein was purified from the soluble fraction by
affinity chromatography using TALON (Clontech,
Mountain View, USA) resin following manufacturer’s
instruction. Bound protein was eluted from the resin
using TALON elution buffer with a step gradient of 50
mM, 80 mM, 100 mM and 150 mM imidazole, collect-
ing ten 500 μL fractions/step. Fractions were analysed
by SDS-PAGE.
Purification of inclusion body aggregates of E2-T1
The insoluble protein fraction (including E2-T1) was
recovered from the IB using BugBuster™ Master Mix
(Novagen-Merck) as follows. IB pellets (equivalent to
160 mL bacterial culture) were resuspended in 2.5 mL
BugBuster™ and vortexed for 2 minutes. Following the
addition of 15 mL of 1:10 diluted BugBuster™ and
further vortexing for 1 minute, the resuspended IB pel-
lets were centrifuged at 5000 g at 4°C for 15 minutes.
Three further washes of 25 mL 1:10 diluted BugBuster™
were performed with vortexing and centrifugation steps
as above. Following the final wash step, the pellets were
resuspended in 1 mL 1:10 diluted BugBuster™,t r a n s -
f e r r e di n t o1 . 5m Lt u b e sa n dc e n t r i f u g e da t1 6 , 2 0 0g at
4°C for 15 minutes. The supernatant was removed and
the IB pellets were stored at -20°C without any detect-
able protein degradation.
Endotoxin Removal
All reagents were prepared in endotoxin-free water (<
0.001 EU/mL, MO BIO Laboratories, Carlsbad, USA).
Triton X-114 exhibits a cloud point at 22°C, above this
temperature micelles aggregate forming a new phase
with very low water content. Endotoxin remains in the
detergent phase [21]. Purified IB pellets were resus-
p e n d e di n1m Lo fP B S( 1 3 7m MN a C l ,2 . 7m MK C l ,
10 mM Phosphate buffer (pH 7.2), Amresco), and vor-
texed for 1 minute to disperse the insoluble protein.
Dispersed protein solutions were mixed with 1% (v/v) of
Triton X-114 by vigorous vortexing for 1 minute. Sam-
ples were incubated on ice for 5 minutes, vortexed and
subsequently incubated at 56°C for 1 minute to allow
phase separation. After centrifugation at 16,200 g
at room temperature for 7 seconds in a microfuge
the 3 phases (aqueous, oil and pellet) were recovered
into separate tubes and analysed by SDS-PAGE
electrophoresis.
To determine the level of endotoxin in the protein
samples, endotoxin assays were performed by using the
Limulus Amebocyte Lysate (LAL) assay by AMS Labora-
tories (Sydney, Australia).
Solubilisation of E2-T1
Protein pellets from the IB preparations were dissolved
in 50 mM Tris (pH 6.8), 100 mM DTT, 1% SDS, 10%
Glycerol, vortexed at low speed for 2 minutes and incu-
bated at 37°C for 20 minutes. The resulting solubilised
protein was dialysed at room temperature, with 3 buffer
changes over 24 hours against 50 mM Tris (pH 7.0),
0.2% Igepal CA630 (Sigma-Aldrich). Following dialysis
protein integrity was determined by SDS-PAGE analysis
and protein yield determined by colourimetric assay
(BioRad DC Kit, Hercules, USA). Other dialysis buffers
evaluated in this study were: 50 mM Tris, (pH 7.0); 50
mM Tris (pH 8.0), 0.2% Igepal CA630; PBS (pH 7.2);
PBS (pH 7.2), Igepal CA630; 50 mM phosphate buffer
(pH 6.0).
SDS-PAGE Electrophoresis
SDS-PAGE analysis was performed using Invitrogen’s
XCell SureLock
® Mini-Cell precast system with
NuPAGE 10% BIS-Tris gels according to manufacturer
instructions. Size estimations were determined against
SeeBlue
® Plus2 (Invitrogen) or Precision Plus Protein
Kaleidoscope Standards (BioRad) pre-stained standards.
The resolved proteins were visualised by staining in 50%
methanol, 10% acetic acid, 0.25% Coomassie Blue R250
for 30 minutes, followed by destaining in 30% methanol,
10% acetic acid for 10 minutes three times.
Western Hybridisation Analysis
Following SDS-PAGE electrophoresis the resolved poly-
peptides were transferred to Hybond C nitrocellulose
membrane (GE Healthcare, Buckinghamshire, United
Kingdom) using Invitrogen XCell II™ Blot Module Kit
according to manufacturer’s instructions. All antibodies
were diluted in BLOTTO (PBS (Amresco), 0.1% Tween
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D89 [29], mAb-157 and mAb-348 [30] and polyclonal
goat anti-BVDV (VMRD, Pullman, USA). The pestivirus
genus specific monoclonal 4-9D4 was kindly provided
by Dr Linfa Wang [31]. E2 specific monoclonal antibo-
dies were used at 1:100 dilution. An anti-E2 sheep sera
804 was produced in vaccinated sheep after intramuscu-
lar injection of BVDV E2 and diluted to 1:500. Mono-
clonal 6× His antibodies (Clontech) were used at
1:15,000. Anti mouse immunoglobulin G HRP conjugate
(Chemicon, Millipore, Billerica, Massachusetts, USA)
and anti sheep/goat immunoglobulin HRP conjugate
(Sigma) were used at 1:2,000 and 1:10,000 respectively.
Detection was carried out using an ECL detection kit
(GE Healthcare).
Animals
C57BL/6J mice were purchased from and housed in the
Biological Resource Facility, The University of Queens-
land, Brisbane, Australia under specific pathogen free
conditions. Female mice were housed in HEPA-filtered
cages with 4 animals per cage in an environmentally
controlled area with a cycle of 12 hours of light and 12
hours of darkness. Food and water were given ad libi-
tum. All studies were conducted with 8 week old mice
at the time of first injection. All procedures were
approved by The University of Queensland Ethics
Committee.
Immunisation of mice with E2-T1
Pre-immunisation blood samples of were collected by
retro-orbital bleed using heparin coated hematocrit
tubes (Hirschmann Laborgeräte Heilbronn, Germany).
Pre-immunisation blood samples collected prior to
the first immunisation were referred to as the preim-
mune samples. Blood samples collected 2 weeks after
the third immunisation wasr e f e r r e dt oa st e r m i n a l
bleed.
All doses of E2-T1 were prepared in sterile conditions
in a certified biological safety cabinet using sterile
reagents, equipment and aseptic technique. The adju-
vant QuilA (Superfos Biosector, Vedback, Denmark) was
resuspended at 2 mg/mL in sterile injectable water (Pfi-
zer, Brooklyn, USA).
Dose volumes were adjusted to 500 μL using 0.9% sal-
ine (Pfizer). 50 μg E2-T1 together with 10 μgQ u i l A ,
were administered in a final volume of 100 μLs u b c u t a -
neously at the tail base using a sterile 27 gauge needle
(Terumo, Tokyo, Japan). Three injections were adminis-
tered at 2 week intervals and mice were sacrificed 14
days after the final immunisation. Animals were closely
monitored throughout the study. All the animals
remained in good health for the duration of the study
with no visible deleterious health effects.
Humoral antibody responses
ELISA assays for the detection of E2-T1-specific antibo-
dies were performed by coating microtitre plates
(96 well, Nunc, Maxisorb, Roskilde, Denmark) with
50 μL E2-T1 antigen solution (2 ng/μLi nP B S )o v e r -
night at room temperature. Antigen solution was
removed from the plates which were then washed once
with 1× PBS-T (1× PBS, 0.1% Tween: Sigma-Aldrich)
and blocked with 200 μL per well of PBS containing 5%
BSA (Sigma-Aldrich), 5% skim milk (Fonterra, Auck-
land, New Zealand) for 1 hour with gentle shaking at
room temperature. Plates were washed three times in
200 μL 1× PBS-T as described above.
Mouse sera samples were diluted from 1:100 to 1:6400
and 50 μL of diluted sera was added to plates then incu-
bated for 2 hours at room temperature. To detect
mouse antibodies HRP conjugated polyclonal sheep
anti-mouse IgG antibodies (100 μL of 1:10000 dilution
in PBS (pH 7.2), Chemicon Australia, Melbourne, Vic,
Australia) was added per well and incubated for 1 hour
at RT with gentle shaking. Plates were washed three
times in 200 μL 1× PBS-T and 100 μL of TMB substrate
(Sigma-Aldrich) was added to each well. After 15 min-
utes at RT 100 μL of 1 N HCl was added to each well
to stop the chromogenic reaction. Plates were read at
450 nm within 10 minutes.
Concentrating of E2-T1/Buffer Change
Protein concentration was increased by using 30 kDa
Vivaspin 2 centrifugal filters (Millipore). Briefly, up to 2
mL of protein solution was added to the upper chamber
and centrifuged (4000 g, 4°C) until the volume was reduced
to the required amount. These columns were also used to
perform buffer changes. After concentration of samples,
the target buffer was replenished to the original volume.
Dynamic light scattering analysis
Size and polydispersity data were determined by
dynamic light scattering (DLS) using a Malvern Instru-
ments Zetasizer Nano (Worcestershire, UK.). E2-T1
solution (1 mL) was placed in a clear disposable zeta
cell (DTS1060C, Malvern Instruments). Analysis was
performed using the size standard operating procedure
(SOP) for which the following parameters were use:
material set to protein, dispersant set to water, taking 5
- 6 independent measurements of 30 runs each. The
size and polydispersity index for samples were the aver-
age of all measurements. Analysis of the data was car-
ried out by Malvern Zetasizer software.
Physical properties of E2-T1
Physical data was obtained using ProtParam, last
accessed 3 March 2011 at http://au.expasy.org/tools/
protparam.html.
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